IFNA1 and B-cell chronic lymphocytic leukemia: Recent work by our group has demonstrated that the CELMoD avadomide can induce type I and II IFN signaling in the T cell compartment that sensitizes CLL to anti-PD-1 or anti-PD-L1 checkpoint blockers (67).